Pexidartinib

INN name:	Pexidartinib
Lab codes:	PLX3397
Chemical name:	5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6 (trifluoromethyl)pyridin-3-yl]methyl}pyridin-2-amine
Molecular formula:	C20H15ClF3N5
Chemical Structure:
CAS Registry Number:	1029044-16-3
Originator:	Plexxikon
Developer:	Barbara Ann Karmanos Cancer Institute; Merck & Co; National Cancer Institute (USA); Plexxikon; University of California at San Francisco
Class:	Antineoplastic
Mechanism of Action:	Tyrosine kinase inhibitor
WHO ATC code:	L01X-E (Protein kinase inhibitors) L04A-A (Selective immunosupressants) M01 (Antiinflammatory and Antirheumatic Products) N06D-X (Other anti-dementia drugs)
EPhMRA code:	L1H (Protein Kinase Inhibitor Antineoplastics) L4X (Other Immunosuppressants) M1 (Anti-Inflammatory and Anti-Rheumatic Products) N6D (Nootropics)
Clinical Trials:
Conditions Phases Interventions Recruitment Pigmented Villonodular Synovitis|Giant Cell Tumors of the Tendon Sheath|Tenosynovial Giant Cell Tumour Phase 3 Alone Recruiting Breast Neoplasms|Breast Cancer|Breast Tumors Phase 2 Combination Recruiting Hodgkin Lymphoma Phase 2 Alone Completed Malignant Melanoma Phase 2 Alone Not yet recruiting Prostate Cancer Phase 2 Alone Completed Recurrent Glioblastoma Phase 2 Alone Completed Acute Myeloid Leukemia Phase 1|Phase 2 Alone Active, not recruiting Gastrointestinal Stromal Tumors Phase 1|Phase 2 Alone and in Combination Suspended Advanced Melanoma and Other Solid Tumors Phase 1|Phase 2 Combination Recruiting Metastatic Breast Cancer Phase 1|Phase 2 Combination Recruiting Neurofibroma, Plexiform|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Prolymphocytic, Acute|Sarcoma Phase 1|Phase 2 Alone Recruiting Patients With Newly Diagnosed Glioblastoma Phase 1|Phase 2 Combination Recruiting Solid Tumors Phase 1 Alone Active, not recruiting Rheumatoid Arthritis Phase 1 Alone Withdrawn Solid Tumors Phase 1 Combination Active, not recruiting Intermediate- or High-Risk Prostate Cancer Phase 1 Alone Recruiting V600-mutated BRAF Melanoma Phase 1 Combination Terminated
Recent activities on the drug: